Our easy-to-read patient fact sheet compares and contrasts sinus arrhythmia vs AFib (atrial fibrillation) symptoms.

If you have symptoms of Afib, you should promptly inform your doctor, who can diagnose it with an electrocardiogram (EKG), a quick test that is typically part of an annual health checkup.

Milestone Pharmaceuticals Inc. announced that the PDUFA date for its nasal spray CARDAMYST™ (etripamil) for treating Paroxysmal Supraventricular Tachycardia (PSVT) has been set for March 27, 2025.

NEW HAVEN, Conn. (WTNH) — In Friday’s Health headlines, February is heart month, and we’re talking about AFib, portable EKG devices, and how stress this season can be hard on the heart.

In patients with symptoms such as irregular heartbeats, dizziness, or fainting, or in individuals that physicians suspect may ...

Etripamil for patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) Phase 3 pivotal trial in AFib-RVR expected to begin enrollment in H1 2025. Milestone plans to initiate a ...

The analyst anticipates significant revenue generation, estimating that CARDAMYST could exceed $1 billion in revenues if approved for both PSVT and AFib-RVR. Trucchio notes that the market ...

It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid ...

Once you cross age 40, you have a 1 in 4 chance of developing AFib. The Heart Rhythm Society ... Simple electrocardiogram (ECG or EKG) technology can measure your heart’s activity.